Research information only · No sales · Not for human use
Educational navigator
Evidence: Moderate — specific populations
A GHRH analogue (tesamorelin) has randomized-trial data for visceral fat in one defined clinical population. Incretin-based medicines also reduce visceral fat as part of overall weight change. Findings do not generalize to unapproved compounds.
Evidence: Strong for approved incretin drugs
Large phase 3 trials support approved, branded GLP-1 and GIP/GLP-1 medicines under medical supervision. Investigational tri-agonists show early results but lack long-term safety data.
Evidence: Limited — mostly topical / in vitro
Copper peptides such as GHK-Cu are studied in topical cosmetic formulations. Evidence is mainly laboratory and small cosmetic studies; injectable use is not established.
Evidence: Limited
Growth-hormone secretagogues alter hormone levels in small studies, but meaningful, safe effects on muscle in healthy people have not been demonstrated.
Evidence: Limited / mixed
Ghrelin-pathway research explores appetite physiology. Clinical evidence for peptide secretagogues in this area is small and inconsistent.
Evidence: Mostly preclinical
BPC-157 and TB-500 literature is dominated by animal and cell studies. Controlled human trials are scarce; safety in humans is not established.
Evidence: Strong for approved drugs
Incretin hormones are among the best-studied metabolic targets, with approved medicines for type 2 diabetes. Research-grade materials are not equivalent.
Evidence: Very limited
No peptide has been shown to slow human aging. Claims in this area generally extrapolate from cell or animal data.